Australia is on track to cure more people of hepatitis C in 2016 alone than in the past 20 years, according to a new report from UNSW's Kirby Institute.
New hepatitis C treatments are expensive but Greg Dore and Marianne Martinello argue that facilitating global access to safe, direct-acting antivirals will herald a revolution.
Professor Miles Davenport, Dr Deborah Cromer, Dr Mykola Pinkevych and, Dr David Khouryfrom the Kirby Institute at UNSW are part of a team in the running for the UNSW Eureka Prize for Excellence in Interdisciplinary Scientific Research.
In fields ranging from infectious diseases and palaeontology, to solar and chemical engineering, ten UNSW researchers and a research institute are finalists in six prestigious Eureka Prizes.
Australian funding of new hepatitis C treatments has provided the therapeutic tools to eliminate the disease as a public health issue within a decade, writes Greg Dore.
Australia is on track to eliminate hepatitis C if record numbers of people living with the virus continue to seek and receive breakthrough antiviral treatment, according to a new analysis.
NSW is on track to virtually eliminate HIV transmission by 2020 as an expanded PrEP trial, led by the Kirby Institute at UNSW, enrols its one thousandth participant in record time.
Overall prevalence of trachoma in Australia is declining as a result of strengthened control programs, according to a surveillance report released today by UNSW’s Kirby Institute.
